Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial
- 1 March 2006
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 9 (2), 77-89
- https://doi.org/10.1111/j.1524-4733.2006.00083.x
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Effectiveness and Cost of Risperidone and Olanzapine for SchizophreniaCNS Drugs, 2005
- Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequencesSchizophrenia Research, 2004
- Assessing the Value of Antipsychotics for Treating SchizophreniaPharmacoEconomics, 2004
- Olanzapine versus Risperidone in the Treatment of SchizophreniaPharmacoEconomics, 2003
- Use and Costs of Ambulatory Care Services Among Medicare Enrollees With SchizophreniaPsychiatric Services, 2001
- Designing Naturalistic Prospective Studies of Economic and Effectiveness Outcomes Associated with Novel Antipsychotic TherapiesValue in Health, 2000
- METHODS FOR ANALYZING HEALTH CARE UTILIZATION AND COSTSAnnual Review of Public Health, 1999
- Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with SchizophreniaNew England Journal of Medicine, 1994
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970
- Explanatory and pragmatic attitudes in therapeutical trialsJournal of Chronic Diseases, 1967